LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 06/01/22

KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting (the "Meeting"). On May 31, 2022 at 1:00 p.m. (Pacific Time), the Compa...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced its receipt of its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs. According to the update, Lexaria has received notification from t...

(TheNewswire) 25 th patent grant is Lexaria’s first-ever patent for the enhanced delivery of antivirals Kelowna, British Columbia – TheNewswire - April 21, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasda...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that it has begun its multi-week human clinical hypertension study. The randomized, double blinded, placebo-controlled, cross-over study in 60 people, HYPER-H21-4, is the most comprehen...

(TheNewswire) HYPER-H21-4 will evaluate DehydraTECH TM -CBD for reducing blood pressure together with other potential clinical benefits This s tudy is designed to enhance Lexaria’s probabilities of success with its ...

Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug Administration KELOWNA, BC / ACCESSWIRE / April 14, 2022 / Lexaria Bioscience Corp. (N...

(TheNewswire) Data from this human study, together with the findings from Lexaria’s other previously announced successful studies, intended to support the Company’s plans to seek approvals by the U.S. Food and Drug Administration K...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. According to the announcement, NIC-H22-1 is a minimum 36-person human pharmacokinetic (“...

Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States suc h as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global ...

(TheNewswire) Kelowna, British Columbia – TheNewswire - April 11, 2022 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, ann...